Max Planck Institute for Infection Biology
Infectious Disease Epidemiology
I am a PhD candidate at Max Planck Institute for Infection Biology, Germany. My current work focuses on the epidemiology of pneumococcal diseases, vaccination strategies, and vaccine impacts. Previously, I have worked as a hospital pharmacist in Hong Kong and as a humanitarian pharmacist in Central African Republic and South Sudan. After conducting a research project on pertussis vaccination policy at Institut Pasteur, Paris and obtaining my Double Master in Public Health with a specialisation in Epidemiology and Biostatistics in the UK and France, I started to pursue my PhD in Health Data Sciences at Charité – Universitätsmedizin Berlin.

Presenter of 1 Presentation

O044 - USING LASSO REGRESSION TO ESTIMATE THE POPULATION-LEVEL IMPACT OF PNEUMOCOCCAL CONJUGATE VACCINES (ID 572)

Session Type
Parallel Session
Date
Tue, 21.06.2022
Session Time
14:50 - 16:20
Room
Grand Ballroom Centre
Lecture Time
14:55 - 15:05

Abstract

Background

The pneumococcal conjugate vaccines (PCVs) protect against diseases caused by Streptococcus pneumoniae, such as meningitis, bacteremia, and pneumonia. Estimating the population-level impact – including direct and indirect effects – of PCVs is challenging because of the lack of a perfect control population and the subtleness of signals when the outcome – like all-cause pneumonia – is attributable to a wide range of pathogens. Here we present a new approach to estimate PCVs’ impacts – using LASSO regression to predict the counterfactual outcome in different age groups for vaccine impact inference.

Methods

First, we designed a simulation study to test the performance of LASSO regression and three established methods – interrupted time series (ITS), synthetic control (SC), and seasonal-trend decomposition plus PCA (STL+PCA) – by comparing their ability to estimate the pre-specified vaccine impact. Then we applied LASSO to published pneumonia hospitalization data from Chile, Ecuador, Mexico, and the US.

Results

In the simulations, we found that both LASSO and SC achieved accurate and precise estimation, with high coverage (LASSO: 96–100%; SC: 69–89%); while estimates from ITS and STL+PCA were sometimes biased, with variable coverage (ITS: 0­–100%; STL+PCA: 0–100%). The performance of LASSO and SC remained robust in complex simulation scenarios where the association between outcome and all control variables was non-causal. When applied to real data, we found that LASSO yielded similar estimates of vaccine impact to SC.

Conclusions

The LASSO method is accurate, easily implementable and interpretable. In complement to existing methods like SC, LASSO can be used to study the population-level impact of PCVs and other vaccines.

Hide